Improving the outcome of liver transplantation with very old donors with updated selection and management criteria

Matteo Cescon, Gian Luca Grazi, Alessandro Cucchetti, Matteo Ravaioli, Giorgio Ercolani, Marco Vivarelli, Antonietta D'Errico, Massimo Del Gaudio, Antonio Daniele Pinna – 23 April 2008 – Advanced donor age is a risk factor for poor outcome in liver transplantation (LT). We reviewed 553 consecutive transplants according to donor age categories [group 1 (n = 173): <50 years; group 2 (n = 96): 50–59 years; group 3 (n = 132): 60–69 years; group 4 (n = 111): 70–79 years; group 5 (n = 41): ≥80 years]. Clinical parameters were comparable between groups.

Cell‐mediated rejection results in allograft loss after liver cell transplantation

Katrina J. Allen, Nicole A. Mifsud, Robert Williamson, Patrick Bertolino, Winita Hardikar – 23 April 2008 – Liver cell transplantation in humans has been impeded by invariable loss of the graft. It is unclear whether graft loss is due to an immune response against donor hepatocytes. Transplantation with ABO‐matched liver cells was performed in a patient with Crigler‐Najjar type 1. After successful engraftment, there was a gradual loss of graft function.

Human T‐cell leukemia virus type I–associated myelopathy following living‐donor liver transplantation

Akihiko Soyama, Susumu Eguchi, Mitsuhisa Takatsuki, Tatsuki Ichikawa, Masako Moriuchi, Hiroyuki Moriuchi, Tatsufumi Nakamura, Yoshitsugu Tajima, Takashi Kanematsu – 23 April 2008 – This report describes a patient who developed human T‐cell leukemia virus type I–associated myelopathy (HAM) following a living‐donor liver transplantation (LDLT) for liver cirrhosis due to hepatitis C virus (HCV) infection. Both the recipient and the living donor (his sister) were human T‐cell leukemia virus type I (HTLV‐I) carriers.

Ischemic cholangiopathy following liver transplantation from donation after cardiac death donors

Edie Y. Chan, Les C. Olson, James A. Kisthard, James D. Perkins, Ramasamy Bakthavatsalam, Jeffrey B. Halldorson, Jorge D. Reyes, Anne M. Larson, Adam E. Levy – 23 April 2008 – The use of donation after cardiac death (DCD) donor hepatic allografts is becoming more widespread; however, there have been published reports of increased graft failure from specific complications associated with this type of allograft. The complication of ischemic cholangiopathy (IC) has been reported to occur more frequently after the use of DCD hepatic allografts.

Metabolic liver disease in children

Keli Hansen, Simon Horslen – 23 April 2008 – The aim of this article is to provide essential information for hepatologists, who primarily care for adults, regarding liver‐based inborn errors of metabolism with particular reference to those that may be treatable with liver transplantation and to provide adequate references for more in‐depth study should one of these disease states be encountered. Liver Transpl 14:713–733, 2008. © 2008 AASLD.

Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistance

Scott Preiss, Margaret Littlejohn, Peter Angus, Alex Thompson, Paul Desmond, Sharon R. Lewin, Joe Sasadeusz, Gail Matthews, Gregory J. Dore, Tim Shaw, Vitini Sozzi, Lilly Yuen, George Lau, Anna Ayres, Chloe Thio, Anchalee Avihingsanon, Kiat Ruxrungtham, Stephen Locarnini, Peter A. Revill – 21 April 2008 – Defective hepatitis B virus DNA (dDNA) is reverse‐transcribed from spliced hepatitis B virus (HBV) pregenomic messenger RNA (pgRNA) and has been identified in patients with chronic HBV (CH‐B).

A novel role for adiponectin in regulating the immune responses in chronic hepatitis C virus infection

Clovis Palmer, Taline Hampartzoumian, Andrew Lloyd, Amany Zekry – 21 April 2008 – Adipose tissue releases pro‐inflammatory and anti‐inflammatory mediators, including adiponectin, which elicit a broad range of metabolic and immunological effects. The study aim was to determine in subjects infected with chronic hepatitis C virus (HCV) the effects of total adiponectin and its high‐molecular‐weight (HMW) and low‐molecular‐weight isoforms on HCV‐specific immune responses. Serum levels of total adiponectin and its isoforms were determined by immunoassay.

Subscribe to